The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.
Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, Huddle BC, Low J, Blankenship KB, Wang Y, Gordon B, Archer P, Brady SW, Natarajan S, Posgai MJ, Schuetz J, Miller D, Kalathur R, Chen S, Connelly JP, Babu MM, Dyer MA, Pruett-Miller SM, Freeman BB 3rd, Chen T, Godley LA, Blanchard SC, Stewart E, Easton J, Geeleher P.
Pan M, et al. Among authors: freeman bb 3rd.
Nat Commun. 2021 Nov 9;12(1):6468. doi: 10.1038/s41467-021-26640-x.
Nat Commun. 2021.
PMID: 34753908
Free PMC article.